Skip to main content
. 2023 Mar 1;3(3):347–360. doi: 10.1158/2767-9764.CRC-22-0365

FIGURE 7.

FIGURE 7

OAd-MSC MyD88−/− also improves the antitumor efficacy of OAd-MSC WT in vivo. A, Follow-up of tumor growth in mice treated with PBS (black), OAd-MSC WT (blue), or OAd-MSC MyD88−/− (yellow) represented as mean + SEM (n = 7). B, Tumor weight of treated mice at endpoint. One-way ANOVA followed by Tukey multiple comparisons tests. C, AUC of treated groups expressed as mean + SEM (n = 7). D, Antitumor activity of OAd-MSC WT and OAd-MSC MyD88−/− in relation to control group (n = 7). E, Schematic illustration of in vivo experimental design. F,In vivo homing of OAd-MSC to tumor site 48 hours after treatment administration, expressed as ex vivo quantification of fluorescence (DIR+) signal in tumors of mice treated with OAd-MSC (n = 7). Unpaired t test. G,In vivo homing of OAd-MSC to different organs extracted at 48 hours, expressed as ex vivo quantification of fluorescence (DIR+) signal in tumors of treated mice. H, Heatmap showing inflammatory cytokines in serum at 48 hours after administration of OAd-MSC WT or OAd-MSC MyD88−/− (pool from n = 4). White represents the lowest expression while dark blue represents the highest expression. I, Immune populations from complete blood count at 48 hours after treatment administration (n = 5–7). One-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05.